Galectin Therapeutics presents NAVIGATE trial findings on portal hypertension in MASH cirrhosis at AASLD 2024. Results expected December 2024.Quiver AI SummaryGalectin Therapeutics, Inc. has announced...
The top four unusually active call options in Thursday trading had an average Vol/OI ratio of 52.25. While that’s not very high, each has compelling reasons to buy. Here's why.
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...
NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...
NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) -- Â Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...